{"id":742124,"date":"2011-04-29T06:00:00","date_gmt":"2011-04-29T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"merck-announces-first-quarter-2011-financial-results","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/","title":{"rendered":"Merck Announces First Quarter 2011 Financial Results"},"content":{"rendered":"<ul>\n<li>         Double-Digit EPS Growth in First Quarter 2011: Non-GAAP EPS of $0.92;          GAAP EPS of $0.34       <\/li>\n<li>         Double-Digit Global Growth for JANUVIA, JANUMET, SINGULAIR, REMICADE,          NASONEX and ISENTRESS; Key Product Launches Underway       <\/li>\n<li>         Pharmaceutical, Animal Health and Consumer Care Divisions All          Contributed Solid Revenue Growth       <\/li>\n<li>         Company Updates Full-Year 2011 EPS Targets: Non-GAAP EPS Range of          $3.66 to $3.76; GAAP EPS Range of $2.04 to $2.39       <\/li>\n<\/ul>\n<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada,        today announced financial results for the first quarter of 2011.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"7\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             $ in millions, except EPS amounts           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2011<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Sales         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             $           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             11,580           <\/p>\n<\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             $           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             11,422           <\/p>\n<\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           GAAP EPS         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.34         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.09         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl1  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Non-GAAP EPS that excludes items listed below <sup>1<\/sup>           <\/p>\n<\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.92         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.83         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             GAAP Net Income <sup>2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,043         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           299         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Non-GAAP Net Income that excludes items listed below <sup>1, 2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,861         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,608         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<\/table>\n<p>       Non-GAAP (generally accepted accounting principles) earnings per share        (EPS) for the first quarter of $0.92 excludes purchase accounting        adjustments, restructuring costs, merger-related expenses, a $500        million charge related to the resolution of the arbitration proceeding        with Johnson &amp; Johnson, and certain other items.     <\/p>\n<p>       A reconciliation of GAAP to non-GAAP net income and EPS is provided in        the tables that follow.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"6\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"6\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"6\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2011<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"6\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">           $ in millions, except EPS amounts         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Net<\/b><br \/><b>Income<\/b><sup>2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">           <b>EPS<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Net<\/b><br \/><b>Income<\/b><sup>2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">           <b>EPS<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">           GAAP         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,043         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.34         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           299         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.09         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">           Difference         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,818         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             0.58           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <sup>3<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,309         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             0.74           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <sup>3<\/sup>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">           Non-GAAP that excludes items listed below         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,861         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.92         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,608         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.83         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           $ in millions         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2011<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Purchase accounting adjustments<sup>4<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,580         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,374         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Costs related to restructuring programs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           126         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           351         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Merger-related costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           77         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           87         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Arbitration settlement charge         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           500         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Other<sup>5<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (134         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Net decrease (increase) in income before taxes         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,149         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,812         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Estimated income tax (benefit) expense <sup>6<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (331         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (503         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Decrease (increase) in net income         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,818         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,309         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<\/table>\n<p>       &#8220;Merck&#8217;s first quarter performance underscores that we are successfully        delivering on our intent to grow both the top line and the bottom line,&#8221;        said Kenneth C. Frazier, president and chief executive officer. &#8220;Our        strong results were largely driven by double-digit growth of key        products combined with deliberate cost control measures across all areas        of the company as we continue to create a more effective and efficient        operating model.     <\/p>\n<p>       &#8220;It is clear that Merck&#8217;s business momentum is building, and we continue        to demonstrate the ongoing value of the merger. We&#8217;re making progress in        our robust late-stage pipeline, and leveraging the benefits of our        expanded pharmaceutical and vaccine, animal health and consumer        portfolio.&#8221;     <\/p>\n<p>       <b>Select Revenue Highlights<\/b>     <\/p>\n<p>       Worldwide sales were $11.6 billion for the first quarter of 2011, an        increase of 1 percent compared with the first quarter of 2010. The        revenue increase largely reflects strong sales of JANUVIA, JANUMET,        SINGULAIR, REMICADE, NASONEX and ISENTRESS, partially offset by lower        sales of COZAAR <sup>7<\/sup> and HYZAAR<sup>7<\/sup>. In the first        quarter of 2011, 18 percent of pharmaceutical sales were from emerging        markets.     <\/p>\n<p>       The table below reflects sales of the company&#8217;s top Pharmaceutical        products, as well as total sales of Animal Health and Consumer Care        products.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             $ in millions           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2011<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>First<\/b><br \/><b>Quarter<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Change<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Total Sales         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           11,580         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           11,422         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Pharmaceutical <sup>8<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           9,820         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           9,665         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           SINGULAIR         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,328         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,165         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           14         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           REMICADE         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           753         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           674         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           12         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           JANUVIA         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           739         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           511         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           45         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           ZETIA         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           582         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           534         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           9         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           VYTORIN         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           480         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           477         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           COZAAR\/HYZAAR         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           426         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           782         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           -46         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           NASONEX         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           373         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           320         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           17         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           JANUMET         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           305         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           201         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           52         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           ISENTRESS         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           292         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           232         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           26         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           TEMODAR         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           248         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           274         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           -10         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">           GARDASIL         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           214         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           233         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           -8         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Animal Health         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           758         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           709         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           7         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Consumer Care <sup>8<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           517         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           489         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           6         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Other Revenues <sup>9<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           486         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           559         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           -13         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<\/table>\n<p>       The combined diabetes franchise for JANUVIA (sitagliptin)\/JANUMET        (sitagliptin\/metformin hydrochloride) continued its strong performance        across all geographic regions during the first quarter of 2011, reaching        quarterly combined sales of more than $1 billion for the first time \u2013 a        47 percent increase compared to the same period last year.     <\/p>\n<p>       Worldwide sales of SINGULAIR (montelukast sodium), a once-a-day oral        medicine indicated for the chronic treatment of asthma and the relief of        symptoms of allergic rhinitis, grew 14 percent from the first quarter of        2010 to $1.3 billion, driven by gains in the United States, emerging        markets and Japan.     <\/p>\n<p>       Global sales grew in the quarter for REMICADE (infliximab), a treatment        for inflammatory diseases, led by increases in gastrointestinal        indications for the treatment of ulcerative colitis and Crohn&#8217;s disease        as well as emerging market gains.     <\/p>\n<p>       ISENTRESS (raltegravir), an HIV integrase inhibitor for use in        combination with other antiretroviral agents for the treatment of HIV-1        infection, continued strong growth in the quarter driven by demand in        the United States and Europe.     <\/p>\n<p>       As expected, global sales of Merck&#8217;s antihypertensive medicines COZAAR        (losartan potassium) and HYZAAR (losartan potassium and        hydrochlorothiazide) continue to decline following loss of marketing        exclusivity for these products in the United States and in major        European markets. Sales of TEMODAR (temozolomide), a treatment for        certain types of brain tumors, declined due to generic competition in        Europe.     <\/p>\n<p>       Sales of ZOSTAVAX (zoster vaccine live) declined due to continued        intermittent supply issues.     <\/p>\n<p>       <b>Product Performance \u2013 Animal Health<\/b>     <\/p>\n<p>       The company drove solid first-quarter performance in the Animal Health        business across all regions, with a 7 percent sales increase over the        same period last year. The growth was led by increased sales of cattle,        swine and aquaculture products. The division&#8217;s products include        pharmaceutical and vaccine products for the prevention, treatment and        control of disease in all major farm and companion animal species. In        addition, in March of 2011, Merck and sanofi-aventis announced the        termination of their agreement to form a new animal health joint venture.     <\/p>\n<p>       <b>Product Performance \u2013 Consumer Care<\/b>     <\/p>\n<p>       Merck Consumer Care delivered a first-quarter sales increase of 6        percent compared to the first quarter of 2010, with strong performance        across several key brands including CLARITIN and COPPERTONE. Consumer        Care includes footcare and suncare consumer products, and a variety of        over-the-counter medicines.     <\/p>\n<p>       <b>First Quarter Expense and Other Information<\/b>     <\/p>\n<p>       The costs detailed below on a GAAP basis during the first quarter of        2011 totaled     <\/p>\n<p>       $9.4 billion and include $1.8 billion of purchase accounting        adjustments, restructuring costs and merger-related costs.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td colspan=\"5\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"12\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"12\">\n<p class=\"bwcellpmargin\">             <b>Included in expenses for the period<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             $ in millions<\/p>\n<p><b>First Quarter 2011<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Purchase<\/b><br \/><b>Accounting<\/b><br \/><b>Adjustments<\/b><sup><b>4<\/b><\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Restructuring<\/b><br \/><b>Costs<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Merger-<\/b><br \/><b>Related<\/b><br \/><b>Costs<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Non-<\/b><br \/><b>GAAP <\/b><sup><b>1<\/b><\/sup>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Materials and production         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           4,059         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,278         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           72         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           19         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,690         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Marketing and administrative         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,164         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           23         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           58         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,083         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Research and development         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,158         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           302         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           45         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,811         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Restructuring costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (14         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (14         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           <b>First Quarter 2010<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Materials and production         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           5,216         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,347         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           57         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,812         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Marketing and administrative         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,222         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           80         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,142         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Research and development         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,051         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           27         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           6         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,018         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Restructuring costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           288         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           288         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<\/tr>\n<\/table>\n<p>       The gross margin was 64.9 percent for the first quarter of 2011 and 54.3        percent for the first quarter of 2010, reflecting 11.9 and 21.1        percentage point unfavorable impacts, respectively, from the purchase        accounting adjustments, restructuring and merger-related costs noted        above.     <\/p>\n<p>       Equity income from affiliates was $138 million in the first quarter.        Equity income from affiliates primarily includes the AstraZeneca LP,        Johnson &amp; Johnson Merck Consumer Pharmaceuticals Company and Sanofi        Pasteur MSD partnerships.     <\/p>\n<p>       Other (income) expense, net was $622 million of expense in the first        quarter of 2011 which includes a $500 million charge related to the        resolution of the arbitration proceeding with Johnson &amp; Johnson. Other        (income) expense, net for the first quarter of 2010 was $167 million of        expense.     <\/p>\n<p>       The GAAP effective tax rate was 38.1 percent for the first quarter of        2011. The non-GAAP effective tax rate, which excludes the impact of        purchase accounting adjustments, restructuring costs, merger-related        expenses, a $500 million charge related to the resolution of the        arbitration proceeding, and certain other items, was 25.5 percent for        the quarter.     <\/p>\n<p>       <b>Key Developments<\/b>     <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">         Merck reached an agreement with Johnson &amp; Johnson that settles the          arbitration proceeding about the distribution rights for REMICADE          (infliximab) and SIMPONI (golimumab).       <\/li>\n<li class=\"bwlistitemmargb\">         Merck now has five investigational medicines under regulatory review          in the United States and European Union (EU), including two that were          accepted for review in the first quarter of 2011.\n<ul>\n<li class=\"bwlistitemmargb\">             VICTRELIS (boceprevir), the company&#8217;s investigational oral              hepatitis C protease inhibitor currently under Priority Review              status by the U.S. Food and Drug Administration (FDA) and              accelerated assessment status by the EU, was recommended for              approval by unanimous vote by the FDA&#8217;s Antiviral Drugs Advisory              Committee on April 27, 2011.           <\/li>\n<li class=\"bwlistitemmargb\">             An investigational extended-release formulation of JANUMET              (sitagliptin\/metformin HCI) for Type 2 diabetes is under standard              review by the FDA.           <\/li>\n<li class=\"bwlistitemmargb\">             The FDA accepted for standard review during the first quarter of              2011 a combination of JANUVIA (sitagliptin) and ZOCOR              (simvastatin)\u00a0for the investigational treatment of diabetes and              dyslipidemia.           <\/li>\n<li class=\"bwlistitemmargb\">             Tafluprost, an investigational prostaglandin analogue ophthalmic              solution, was accepted for standard review by the FDA in the first              quarter of 2011.           <\/li>\n<li class=\"bwlistitemmargb\">             NOMAC-E2 (acetate 2.5 mg \/17\u03b2-estradiol 1.5 mg), an              investigational monophasic combined oral contraceptive tablet for              the use by women to prevent pregnancy was recommended for approval              by the Committee for Medicinal Products for Human Use of the              European Medicines Agency.           <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">         Two medicines received regulatory approval for expanded indications.\n<ul>\n<li class=\"bwlistitemmargb\">             In the United States, ZOSTAVAX (Zoster Vaccine Live) received an              expanded age indication for the prevention of herpes zoster,              commonly known as shingles, to include adults 50 to 59 years of              age, and           <\/li>\n<li class=\"bwlistitemmargb\">             In the EU, SIMPONI (golimumab) received approval for use in              combination with methotrexate in certain adults with severe,              active and progressive rheumatoid arthritis for the reduction in              the rate of progression of joint damage as measured by X-ray.           <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">         In the United States, the FDA approved SYLATRON (peginterferon          alfa-2b) for the adjuvant treatment of patients with melanoma with          microscopic or gross nodal involvement within 84 days of definitive          surgical resection including complete lymphadenectomy.       <\/li>\n<li class=\"bwlistitemmargb\">         The company formed a new joint venture with Sun Pharmaceutical          Industries Ltd., a leading Indian multinational pharmaceutical          company, to develop, manufacture and commercialize new combinations          and formulations of innovative, branded generics for the emerging          markets.       <\/li>\n<li class=\"bwlistitemmargb\">         Merck agreed to acquire Inspire Pharmaceuticals, Inc., a specialty          pharmaceutical company, for approximately $430 million to expand and          position its ophthalmology portfolio for future growth. The          transaction is expected to close in the second quarter of 2011.       <\/li>\n<\/ul>\n<p>       <b>Financial Targets<\/b>     <\/p>\n<p>       The company updated its 2011 non-GAAP EPS target range to $3.66 to $3.76        from the previous target range of $3.64 to $3.76. The target range        excludes purchase accounting adjustments, restructuring costs,        merger-related expenses, the $500 million charge related to the        resolution of the arbitration proceeding with Johnson &amp; Johnson, and        certain other items. The 2011 GAAP EPS target range is $2.04 to $2.39.     <\/p>\n<p>       In addition, the company lowered its non-GAAP R&amp;D expense target to a        range of $8.0 billion to $8.4 billion for the full year of 2011. This        target excludes restructuring costs and in-process R&amp;D impairment        charges.     <\/p>\n<p>       Merck continues to expect full year 2011 revenue to grow in the low- to        mid-single digit percent range from a base of $46.0 billion in 2010.     <\/p>\n<p>       Merck continues to estimate that its consolidated non-GAAP 2011 tax rate        will be approximately 20 percent to 22 percent.     <\/p>\n<p>       A reconciliation of anticipated 2011 EPS as reported in accordance with        GAAP to non-GAAP EPS that excludes certain items is provided in the        table below.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           $ in millions, except EPS amounts         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Full Year 2011<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           GAAP EPS         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           $2.04 to $2.39         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             EPS difference<sup>3<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           1.62 to 1.37         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Non-GAAP EPS that excludes items listed below         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           $3.66 to $3.76         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Purchase accounting adjustments <sup>4<\/sup>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           $5,400 to $5,100         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Costs related to restructuring programs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           900 to 700         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Merger-related costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           200 to 100         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Arbitration settlement charge         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           500         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">           Other <sup>5<\/sup>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           (134)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Net decrease (increase) in income before taxes         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           6,866 to 6,266         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Estimated income tax (benefit) expense <sup>10<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           (1,840) to (2,000)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">           Decrease (increase) in net income         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           $5,026 to $4,266         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<\/table>\n<p>       <b>Total Employees<\/b>     <\/p>\n<p>       As of March 31, 2011, Merck had approximately 93,000 employees worldwide.     <\/p>\n<p>       <b>Earnings Conference Call<\/b>     <\/p>\n<p>       Investors are invited to a live audio webcast of Merck&#8217;s first quarter        earnings conference call today at 8:00 a.m. EDT by visiting Merck&#8217;s Web        site, <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;esheet=6703017&amp;lan=en-US&amp;anchor=www.merck.com%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;index=1&amp;md5=a4a7070cd46b3ab91eabd9a76b27641f\">www.merck.com\/investors\/events-and-presentations\/home.html<\/a>.        Institutional investors and analysts can participate in the call by        dialing (706) 758-9927 or (877) 381-5782. Journalists are invited to        monitor the call by dialing (706) 758-9928 or (800) 399-7917. A replay        of the call will be available starting at 11 a.m. EDT today for        approximately one week. To listen to the replay, dial (706) 645-9291 or        (800) 642-1687 and enter ID No. 51049889.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6703017&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=2&amp;md5=2805ebb09d0a75c767929c58fe3e2e9a\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6703017&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=88e789bd41d6d21d224f9f3d864785bd\">www.sec.gov<\/a>).     <\/p>\n<p>       <sup>1 <\/sup>Merck is providing certain 2011 and 2010 non-GAAP        information that excludes certain items because of the nature of these        items and the impact they have on the analysis of underlying business        performance and trends. Management believes that providing this        information enhances investors&#8217; understanding of the company&#8217;s        performance. This information should be considered in addition to, but        not in lieu of, information prepared in accordance with GAAP. For a        description of the items, see Table 2a, including the related footnotes,        attached to this release.     <\/p>\n<p>       <sup>2 <\/sup>Net income attributable to Merck &amp; Co., Inc.     <\/p>\n<p>       <sup>3 <\/sup>Represents the difference between calculated GAAP EPS and        calculated non-GAAP EPS which may be different than the amount        calculated by dividing the impact of the excluded items by the weighted        average shares.     <\/p>\n<p>       <sup>4 <\/sup>Amounts for the first quarter of 2011 and 2010 reflect $302        million and $27 million, respectively, of in-process research and        development impairment charges. The remaining amounts represent expenses        for the amortization of intangible assets and amortization of purchase        accounting adjustments to inventories recognized as a result of the        merger.     <\/p>\n<p>       <sup>5 <\/sup>Represents a gain on the sale of certain manufacturing        facilities and related assets reflected in other (income) expense, net.     <\/p>\n<p>       <sup>6 <\/sup>Includes an estimated income tax (benefit) expense on the        reconciling items. In addition, amount for the first quarter of 2010        includes a $147 million tax charge related to U.S. healthcare reform        legislation.     <\/p>\n<p>       <sup>7<\/sup> COZAAR and HYZAAR are registered trademarks of E.I. duPont        de Nemours and Company, Wilmington, Del.     <\/p>\n<p>       <sup>8 <\/sup>In the first quarter of 2011, Merck changed the reporting        for certain over-the-counter products. Sales of these products outside        the United States were previously recorded in the Pharmaceutical        business, and are now reported in the Consumer Care business. Prior        period amounts have been recast on a comparative basis.     <\/p>\n<p>       <sup>9 <\/sup>Other revenues are primarily comprised of alliance revenue,        miscellaneous corporate revenues and third party manufacturing sales.        Revenue from AstraZeneca LP recorded by Merck was $322 million in the        first quarter of 2011.     <\/p>\n<p>       <sup>10 <\/sup>Includes an estimated income tax (benefit) expense on the        reconciling items as well as a range of estimated tax benefits expected        to be recorded in the second quarter as a result of the conclusion of        federal tax audits.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td colspan=\"7\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"7\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"7\">\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED STATEMENT OF OPERATIONS &#8211; GAAP<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"7\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"7\">\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"7\">\n<p class=\"bwcellpmargin\">             <b>Table 1<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">           <b>GAAP<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwpadb1  bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>1Q11<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>1Q10<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>% Change<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 11,580         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 11,422         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           1%         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Costs, Expenses and Other         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">           Materials and production <sup>(1)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,059         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5,216         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -22%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">           Marketing and administrative <sup>(1) \/ (2)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,164         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,222         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -2%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">           Research and development <sup>(1) \/ (2)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,158         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,051         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           5%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">           Restructuring costs <sup>(3)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (14)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           288         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">           *         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">           Equity income from affiliates <sup>(4)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (138)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (138)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           &#8211;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">           Other (income) expense, net <sup>(1) \/<\/sup> <sup>(5)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           622         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           167         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">           *         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Income Before Taxes         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,729         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           616         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">           *         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Income Tax Provision         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           658         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           286         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Net Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,071         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           330         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">           *         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           28         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           31         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Net Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 1,043         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 299         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">           *         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">           Earnings per Common Share Assuming Dilution <sup>(6)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 0.34         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 0.09         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignc\">           *         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Average Shares Outstanding Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,104         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,141         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">           Tax Rate <sup>(7)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           38.1%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           46.4%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           *\u2265 100%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">           (1) Amounts include the impact of purchase accounting adjustments,            restructuring costs, merger-related costs and certain other items.            See accompanying tables for details.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">           (2) The first quarter of 2010 includes a $24 million            reclassification of certain expenses from marketing and            administrative to research and development.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">           (3) Represents separation and other related costs associated with            restructuring activities.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">           (4) Primarily reflects equity income from AstraZeneca LP, Johnson &amp;            Johnson\u00baMerck Consumer Pharmaceuticals Company and Sanofi Pasteur            MSD partnerships.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">           (5) Other (income) expense, net in the first quarter of 2011            includes a charge of $500 million related to the resolution of the            arbitration proceeding with Johnson &amp; Johnson and a $134 million            gain on the sale of certain manufacturing facilities and related            assets. Other (income) expense, net in the first quarter of 2010            includes $102 million of income on the settlement of certain            disputed royalties and $80 million of exchange losses due to a            Venezuelan currency devaluation.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">           (6) The company calculates earnings per share pursuant to the            two-class method which requires the allocation of net income between            common shareholders and participating security holders. Net income            attributable to Merck &amp; Co., Inc. common shareholders used to            calculate earnings per common share assuming dilution was $1,040            million and $298 million for the first quarter of 2011 and 2010,            respectively.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">           (7) The GAAP effective tax rate for the first quarter of 2011 was            38.1%. Excluding the impact of the non-GAAP items detailed in the            accompanying table, the effective tax rate was 25.5% for the first            quarter of 2011. The GAAP effective tax rate for the first quarter            of 2010 was 46.4%. Excluding the impact of the non-GAAP items            detailed in the accompanying table, the effective tax rate was 23.0%            for the first quarter of 2010.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED STATEMENT OF OPERATIONS<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>GAAP TO NON-GAAP RECONCILIATION<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>FIRST QUARTER 2011<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>Table 2a<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>GAAP<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Purchase Accounting<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <sup>(1)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Restructuring Costs <\/b><sup>(2)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Merger-Related Costs <\/b><sup>(3)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Certain\u00a0Other Items <\/b><sup>(4)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Adjustment Subtotal<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Non-GAAP<\/b>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$ 11,580<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 11,580         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Materials and production         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>4,059<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,278         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           72         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           19         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,369         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,690         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Marketing and administrative         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,164<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           23         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           81         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,083         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Research and development         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,158<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           302         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           347         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,811         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Restructuring costs         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(14)<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (14)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (14)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Equity income from affiliates         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(138)<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (138)         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Other (income) expense, net         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>622<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           366         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           366         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           256         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Income Before Taxes         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,729<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (1,580)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (126)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (77)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (366)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (2,149)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,878         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Taxes on Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>658<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (331)         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <sup>(5)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           989         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,071<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (1,818)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,889         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>28<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           28         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$ 1,043<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ (1,818)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 2,861         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Earnings per Common Share Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$ 0.34<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 0.92         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <sup>(6)<\/sup>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Average Shares Outstanding Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,104<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,104         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Tax Rate         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>38.1%<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           25.5%         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           Merck is providing non-GAAP information that excludes certain items            because of the nature of these items and the impact they have on the            analysis of underlying business performance and trends. Management            believes that providing this information enhances investors&#8217;            understanding of the company&#8217;s performance. This information should            be considered in addition to, but not in lieu of, information            prepared in accordance with GAAP.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (1) Amounts included in materials and production costs reflect            expenses for the amortization of intangible assets and the            amortization of purchase accounting adjustments to inventories            recognized as a result of the merger. Amounts included in research            and development expenses represent in-process research and            development (\u201cIPR&amp;D\u201d) impairment charges.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (2) Amounts primarily include employee separation costs and            accelerated depreciation associated with facilities to be closed or            divested.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (3) Merger-related costs include integration costs associated with            the merger.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (4) Included in other (income) expense, net is a $500 million charge            related to the resolution of the arbitration proceeding with Johnson            &amp; Johnson and a $134 million gain on the sale of certain            manufacturing facilities and related assets.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (5) Represents the estimated tax impact on the reconciling items.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (6) The company calculates earnings per share pursuant to the            two-class method which requires the allocation of net income between            common shareholders and participating security holders. Net income            attributable to Merck &amp; Co., Inc. common shareholders used to            calculate non-GAAP earnings per common share assuming dilution was            $2,853 million for the first quarter of 2011.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"15\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"15\">\n<p class=\"bwcellpmargin\">             <b>FRANCHISE \/ KEY PRODUCT SALES<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"15\">\n<p class=\"bwcellpmargin\">             <b>FIRST QUARTER 2011<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"15\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"15\">\n<p class=\"bwcellpmargin\">             <b>Table 3<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td colspan=\"9\">         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>2011<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"9\">           <b>2010<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>% Change<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">           <b>1Q<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">           <b>1Q<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">           <b>2Q<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">           <b>3Q<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">           <b>4Q<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Full Year<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>1Q<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           <b>TOTAL SALES <\/b><sup><b>(1)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$11,580<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$11,422<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$11,346<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$11,125<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$12,094<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$45,987<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>1<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>PHARMACEUTICAL <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9,820<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9,665<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9,638<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9,523<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>10,441<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>39,267<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Cardiovascular<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Zetia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           582         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           534         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           564         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           571         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           629         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,297         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Vytorin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           480         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           477         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           490         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           485         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           562         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,014         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Integrilin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           64         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           70         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           70         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           63         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           63         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           266         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Diabetes &amp; Obesity<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Januvia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           739         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           511         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           600         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           600         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           675         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,385         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Janumet         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           305         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           201         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           218         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           247         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           288         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           954         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           52         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Diversified Brands<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Cozaar \/ Hyzaar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           426         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           782         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           485         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           423         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           415         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,104         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -46         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Zocor         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           127         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           116         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           117         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           114         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           468         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Claritin Rx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           120         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           98         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           86         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           296         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           23         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Propecia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           106         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           100         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           113         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           109         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           124         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           447         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Proscar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           60         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           44         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           216         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Remeron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           60         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           51         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           50         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           62         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           223         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Vasotec \/ Vaseretic         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           57         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           63         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           69         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           64         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           255         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -4         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Infectious Disease<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Isentress         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           292         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           232         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           267         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           278         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           313         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,090         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           26         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           PegIntron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           166         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           186         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           185         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           168         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           198         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           737         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -11         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Cancidas         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           158         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           153         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           150         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           174         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           611         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Primaxin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           136         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           159         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           158         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           158         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           610         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Avelox         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           106         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           106         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           92         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           316         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Invanz         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           87         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           75         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           83         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           91         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           113         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           362         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           16         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Noxafil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           50         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           52         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           48         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           198         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Rebetol         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           54         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           221         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Crixivan \/ Stocrin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           52         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           48         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           206         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -13         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Neurosciences &amp; Ophthalmology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Maxalt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           173         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           133         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           133         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           149         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           550         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           29         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Cosopt \/ Trusopt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           114         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           115         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           123         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           114         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           131         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           484         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Oncology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Temodar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           248         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           274         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           271         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           254         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           266         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,065         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -10         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Emend         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           87         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           84         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           93         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           91         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           110         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           378         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Intron A         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           54         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           51         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           50         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           54         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           209         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -11         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Respiratory &amp; Immunology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Singulair         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,328         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,165         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,258         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,215         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,349         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,987         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Remicade         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           753         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           674         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           669         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           661         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           710         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,714         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Nasonex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           373         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           320         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           338         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           259         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           303         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,219         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           17         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Clarinex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           164         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           191         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           131         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           138         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           623         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Arcoxia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           114         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           95         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           95         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           94         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           115         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           398         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           19         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Asmanex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           60         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           51         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           48         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           208         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           17         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Simponi         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           54         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           27         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           42         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           97         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr\">           *         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Proventil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           42         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           57         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           43         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           210         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -26         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Dulera         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           13         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr\">           *         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Vaccines<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           ProQuad, M-M-R II and Varivax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           244         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           319         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           340         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           434         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           285         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,378         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -23         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Gardasil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           214         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           233         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           219         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           316         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           221         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           988         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           RotaTeq         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           125         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           93         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           139         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           119         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           169         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           519         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           35         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Pneumovax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           79         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           51         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           110         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           156         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           376         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Zostavax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           24         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           95         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           23         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           107         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           243         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -74         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Women&#8217;s Health &amp; Endocrine<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Fosamax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           208         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           230         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           241         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           220         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           234         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           926         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -10         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           NuvaRing         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           142         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           145         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           134         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           145         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           559         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Follistim AQ         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           133         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           134         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           137         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           119         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           138         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           528         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8212;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Implanon         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           60         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           51         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           51         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           64         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           71         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           236         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12 bwvertalignt bwalignl\">           Cerazette         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           209         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           <b>Other Pharmaceutical <\/b><sup><b>(3)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           745         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           946         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           941         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           942         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,044         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,879         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -21         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>ANIMAL HEALTH<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>758<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>709<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>731<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>687<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>815<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,941<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>7<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>CONSUMER CARE <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>517<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>489<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>544<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>409<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>381<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,823<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>6<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwvertalignt bwalignl\">           Claritin OTC         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           167         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           136         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           167         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           120         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           103         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           526         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           22         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Other Revenues <\/b><sup><b>(4)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>486<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>559<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>433<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>506<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>457<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,956<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>-13<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwpadb1 bwvertalignt bwalignl\">           Astra         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           322         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           364         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           241         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           345         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           302         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,252         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           -11         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           * 100% or over         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"15\">           Sum of quarterly amounts may not equal year-to-date amounts due to            rounding.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"15\">           <sup>(1)<\/sup> Only select products are shown.         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"15\">           <sup>(2)<\/sup> In the first quarter of 2011, Merck changed the            reporting for certain over-the-counter products. Sales of these            products outside the United States were previously recorded in the            Pharmaceutical business, and are now reported in the Consumer Care            business. Prior period amounts have been recast on a comparative            basis.         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"15\">           <sup>(3)<\/sup> Includes pharmaceutical products not individually            shown above. Other vaccines sales included in Other Pharmaceutical            were $54 million for the first quarter of 2011. Other vaccines sales            included in Other Pharmaceutical were $55 million, $57 million, $94            million and $75 million for the first, second, third and fourth            quarters of 2010, respectively.         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"15\">           <sup>(4) <\/sup>Other revenues are primarily comprised of alliance            revenue, miscellaneous corporate revenues and third party            manufacturing sales.         <\/td>\n<\/tr>\n<\/table>\n<p><p>       Media Contacts:<br \/>Steven Campanini, 908-423-4291<br \/>David Caouette,        908-423-3461<br \/>or<br \/>Investor Contacts:<br \/>Carol Ferguson,        908-423-4465<br \/>Joe Romanelli, 908-423-5088     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Double-Digit EPS Growth in First Quarter 2011: Non-GAAP EPS of $0.92; GAAP EPS of $0.34 Double-Digit Global Growth for JANUVIA, JANUMET, SINGULAIR, REMICADE, NASONEX and ISENTRESS; Key Product Launches Underway Pharmaceutical, Animal Health and Consumer Care Divisions All Contributed Solid Revenue Growth Company Updates Full-Year 2011 EPS Targets: Non-GAAP EPS Range of $3.66 to $3.76; GAAP EPS Range of $2.04 to $2.39 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011. $ in millions, except EPS amounts First <br \/>Quarter <br \/>2011 First Quarter 2010 Sales $ 11,580 $ 11,422 GAAP EPS 0.34 0.09 Non-GAAP EPS that excludes items listed below 1 0.92 \u00a0 \u00a0 \u00a0 0.83 \u00a0 GAAP Net Income 2 1,043 299 Non-GAAP Net Income that excludes items listed below 1, 2 2,861 \u00a0 \u00a0 \u00a0 2,608 \u00a0 \u00a0 Non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.92 excludes purchase accounting<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[52,289],"class_list":["post-742124","news_item","type-news_item","status-publish","hentry","tag-financial-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces First Quarter 2011 Financial Results - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces First Quarter 2011 Financial Results - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Double-Digit EPS Growth in First Quarter 2011: Non-GAAP EPS of $0.92; GAAP EPS of $0.34 Double-Digit Global Growth for JANUVIA, JANUMET, SINGULAIR, REMICADE, NASONEX and ISENTRESS; Key Product Launches Underway Pharmaceutical, Animal Health and Consumer Care Divisions All Contributed Solid Revenue Growth Company Updates Full-Year 2011 EPS Targets: Non-GAAP EPS Range of $3.66 to $3.76; GAAP EPS Range of $2.04 to $2.39 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011. $ in millions, except EPS amounts First Quarter 2011 First Quarter 2010 Sales $ 11,580 $ 11,422 GAAP EPS 0.34 0.09 Non-GAAP EPS that excludes items listed below 1 0.92 \u00a0 \u00a0 \u00a0 0.83 \u00a0 GAAP Net Income 2 1,043 299 Non-GAAP Net Income that excludes items listed below 1, 2 2,861 \u00a0 \u00a0 \u00a0 2,608 \u00a0 \u00a0 Non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.92 excludes purchase accounting\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2011-financial-results\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2011-financial-results\\\/\",\"name\":\"Merck Announces First Quarter 2011 Financial Results - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-04-29T06:00:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2011-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2011-financial-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-quarter-2011-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces First Quarter 2011 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces First Quarter 2011 Financial Results - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces First Quarter 2011 Financial Results - Merck.com","og_description":"Double-Digit EPS Growth in First Quarter 2011: Non-GAAP EPS of $0.92; GAAP EPS of $0.34 Double-Digit Global Growth for JANUVIA, JANUMET, SINGULAIR, REMICADE, NASONEX and ISENTRESS; Key Product Launches Underway Pharmaceutical, Animal Health and Consumer Care Divisions All Contributed Solid Revenue Growth Company Updates Full-Year 2011 EPS Targets: Non-GAAP EPS Range of $3.66 to $3.76; GAAP EPS Range of $2.04 to $2.39 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011. $ in millions, except EPS amounts First Quarter 2011 First Quarter 2010 Sales $ 11,580 $ 11,422 GAAP EPS 0.34 0.09 Non-GAAP EPS that excludes items listed below 1 0.92 \u00a0 \u00a0 \u00a0 0.83 \u00a0 GAAP Net Income 2 1,043 299 Non-GAAP Net Income that excludes items listed below 1, 2 2,861 \u00a0 \u00a0 \u00a0 2,608 \u00a0 \u00a0 Non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.92 excludes purchase accounting","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/","name":"Merck Announces First Quarter 2011 Financial Results - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-04-29T06:00:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-quarter-2011-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces First Quarter 2011 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ea81b17c-0615-4cf2-8c12-6d57ba1d2b2a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742124\/revisions"}],"predecessor-version":[{"id":3679260,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742124\/revisions\/3679260"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742124"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}